Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 24833276)

1.

Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201).

Dagley A, Ennis J, Turner JD, Rood KA, Van Wettere AJ, Gowen BB, Julander JG.

Antiviral Res. 2014 Aug;108:1-9. doi: 10.1016/j.antiviral.2014.05.004. Epub 2014 May 14.

PMID:
24833276
2.

Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201).

Smee DF, Wong MH, Russell A, Ennis J, Turner JD.

PLoS One. 2011;6(10):e26330. doi: 10.1371/journal.pone.0026330. Epub 2011 Oct 13.

3.

Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model.

Kumaki Y, Ennis J, Rahbar R, Turner JD, Wandersee MK, Smith AJ, Bailey KW, Vest ZG, Madsen JR, Li JK, Barnard DL.

Antiviral Res. 2011 Jan;89(1):75-82. doi: 10.1016/j.antiviral.2010.11.007. Epub 2010 Nov 18.

4.

A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence.

Morrison TE, Oko L, Montgomery SA, Whitmore AC, Lotstein AR, Gunn BM, Elmore SA, Heise MT.

Am J Pathol. 2011 Jan;178(1):32-40. doi: 10.1016/j.ajpath.2010.11.018. Epub 2010 Dec 23.

5.

Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.

Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, Morrison TE.

J Virol. 2013 Dec;87(24):13878-88. doi: 10.1128/JVI.02666-13. Epub 2013 Oct 16.

6.

Proteomic profiling of chikungunya virus-infected human muscle cells: reveal the role of cytoskeleton network in CHIKV replication.

Issac TH, Tan EL, Chu JJ.

J Proteomics. 2014 Aug 28;108:445-64. doi: 10.1016/j.jprot.2014.06.003. Epub 2014 Jun 14.

PMID:
24933005
7.
8.

Chikungunya virus arthritis in adult wild-type mice.

Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, Schroder WA, Higgs S, Suhrbier A.

J Virol. 2010 Aug;84(16):8021-32. doi: 10.1128/JVI.02603-09. Epub 2010 Jun 2.

9.

Characterization of chikungunya virus induced host response in a mouse model of viral myositis.

Dhanwani R, Khan M, Lomash V, Rao PV, Ly H, Parida M.

PLoS One. 2014 Mar 25;9(3):e92813. doi: 10.1371/journal.pone.0092813. eCollection 2014.

10.

Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.

Partidos CD, Weger J, Brewoo J, Seymour R, Borland EM, Ledermann JP, Powers AM, Weaver SC, Stinchcomb DT, Osorio JE.

Vaccine. 2011 Apr 5;29(16):3067-73. doi: 10.1016/j.vaccine.2011.01.076. Epub 2011 Feb 5.

11.
12.

TLR3 mediated innate immune response in mice brain following infection with Chikungunya virus.

Priya R, Patro IK, Parida MM.

Virus Res. 2014 Aug 30;189:194-205. doi: 10.1016/j.virusres.2014.05.010. Epub 2014 Jun 4.

PMID:
24905288
13.

Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection.

Chen W, Foo SS, Taylor A, Lulla A, Merits A, Hueston L, Forwood MR, Walsh NC, Sims NA, Herrero LJ, Mahalingam S.

J Virol. 2015 Jan;89(1):581-93. doi: 10.1128/JVI.02034-14. Epub 2014 Oct 22.

PMID:
25339772
14.

Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection.

O'Brien L, Perkins S, Williams A, Eastaugh L, Phelps A, Wu J, Phillpotts R.

J Gen Virol. 2009 Apr;90(Pt 4):874-82. doi: 10.1099/vir.0.006833-0. Epub 2009 Mar 4.

15.

Dendritic cell immunoreceptor regulates Chikungunya virus pathogenesis in mice.

Long KM, Whitmore AC, Ferris MT, Sempowski GD, McGee C, Trollinger B, Gunn B, Heise MT.

J Virol. 2013 May;87(10):5697-706. doi: 10.1128/JVI.01611-12. Epub 2013 Mar 13.

16.

A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease.

Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Desprès P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M.

PLoS Pathog. 2008 Feb 8;4(2):e29. doi: 10.1371/journal.ppat.0040029.

17.

Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor.

Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, Barkham T, Yang H, Rénia L, Leo YS, Ng LF.

J Infect Dis. 2011 Jan 15;203(2):149-57. doi: 10.1093/infdis/jiq042.

18.

Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity.

Messaoudi I, Vomaske J, Totonchy T, Kreklywich CN, Haberthur K, Springgay L, Brien JD, Diamond MS, Defilippis VR, Streblow DN.

PLoS Negl Trop Dis. 2013 Jul 25;7(7):e2343. doi: 10.1371/journal.pntd.0002343. Print 2013.

19.

Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.

Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS.

J Virol. 2014 Aug;88(15):8213-26. doi: 10.1128/JVI.01032-14. Epub 2014 May 14.

20.

Copy number variation of Chikungunya ECSA virus with disease symptoms among Indian patients.

Dutta SK, Pal T, Saha B, Mandal S, Tripathi A.

J Med Virol. 2014 Aug;86(8):1386-92. doi: 10.1002/jmv.23794. Epub 2013 Oct 16.

PMID:
24132555
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk